Pyridoxine (vitamin B6)

DIETARY_SUPPLEMENT4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionHIV InfectionsLTBITuberculosisTuberculosis, MDR

Phase 1

Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women

CompletedNCT02651259

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis

Start: 2017-03-13End: 2019-04-10Updated: 2021-11-04

Phase 2

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

TerminatedNCT04272242

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection, LTBI

Start: 2021-02-27End: 2021-12-27Updated: 2024-09-19

Phase 3

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

CompletedNCT01404312

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Tuberculosis

Start: 2012-05-23End: 2017-11-14Updated: 2021-11-04

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Active, not recruitingNCT03568383

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis, MDR

Start: 2019-06-03End: 2027-01-11Updated: 2025-06-15

Related Papers

Update on multidrug-resistant tuberculosis preventive therapy toward the global tuberculosis elimination.

2025-02-229 citations

Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention

Clinical Infectious Diseases2024-04-035 citations

Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.

2022-08-094 citations

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women

Clinical Infectious Diseases2021-07-2830 citations

Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine

Pharmacogenetics and Genomics2020-08-1712 citations

Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials

Clinical Infectious Diseases2019-08-096 citations

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis

New England Journal of Medicine2019-03-13346 citations